glp-1 and prostate cancer Targeting obesity, metabolic syndrome, cancer: agonists as emerging therapeutic agents | Discover Oncology Glucagon-like peptide 1 receptor agonists

However, the journey from promising animal data to effective human therapies is fraught with substantial challenges that must be balanced against the initial optimism

Polygenic Risk Score (PRS) estimates your lifetime risk for major conditions like heart disease, stroke, diabetes, Alzheimers, osteoporosis, and several cancers (including breast, prostate, and ovarian)

Evidence suggests GLP-1 medications can reduce inflammation, pain, and disease activity in several forms of arthritis, especially when obesity or insulin resistance is also present

Capsule format, practical and easy to consume

PubMed Central, Kummer, Wolfgang, and Klaus Deckmann